Sarepta Therapeutics (SRPT) Return on Capital Employed (2011 - 2026)
Sarepta Therapeutics' quarterly Return on Capital Employed came in at 1.48% in Q1 2026, up 229.0% year-on-year from 0.45% in Q1 2025, and up 95.08% quarter-over-quarter from 30.08% in Q4 2025.
Sarepta Therapeutics has reported Return on Capital Employed for 16 years, with the latest figure at 1.48% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 229.0% year-over-year to 1.48%; the trailing twelve-month figure through Mar 2026 stood at 1.48% (up 229.0% YoY), and the FY2025 full-year result was 27.32%, down 3489.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 1.48%, up from 30.08% in the prior quarter.
- The five-year high for Return on Capital Employed was 7.15% in Q4 2024, with the low at 30.08% in Q4 2025.
- Average Return on Capital Employed over 5 years is 10.35%, with a median of 10.57% recorded in 2023.
- Year-over-year, Return on Capital Employed surged 2109 bps in 2024 and sank 3723 bps in 2025.
- Tracing SRPT's Return on Capital Employed over 5 years: stood at 21.26% in 2022, then surged by 50 bps to 10.57% in 2023, then soared by 168 bps to 7.15% in 2024, then sank by 521 bps to 30.08% in 2025, then surged by 95 bps to 1.48% in 2026.
- The last three Return on Capital Employed figures came in at 1.48% (Q1 2026), 30.08% (Q4 2025), and 4.75% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Sarepta Therapeutics | 1.86 Bn | 1.17 Bn | 291.52 Mn | -1.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.48% |
| Dec 31, 2025 | -30.08% |
| Sep 30, 2025 | -4.75% |
| Jun 30, 2025 | -0.04% |
| Mar 31, 2025 | -3.77% |
| Dec 31, 2024 | 7.15% |
| Sep 30, 2024 | 2.88% |
| Jun 30, 2024 | 1.44% |
| Mar 31, 2024 | -3.60% |
| Dec 31, 2023 | -10.57% |
| Sep 30, 2023 | -14.97% |
| Jun 30, 2023 | -19.65% |
| Mar 31, 2023 | -22.97% |
| Dec 31, 2022 | -21.26% |
| Sep 30, 2022 | -21.64% |
| Jun 30, 2022 | -17.67% |
| Mar 31, 2022 | -14.91% |
| Dec 31, 2021 | -18.75% |
| Sep 30, 2021 | -22.45% |
| Jun 30, 2021 | -26.84% |
| Mar 31, 2021 | -23.82% |
| Dec 31, 2020 | -22.87% |
| Sep 30, 2020 | -25.42% |
| Jun 30, 2020 | -23.83% |
| Mar 31, 2020 | -35.95% |
| Dec 31, 2019 | -47.10% |
| Sep 30, 2019 | -40.73% |
| Jun 30, 2019 | -33.13% |
| Mar 31, 2019 | -23.37% |
| Dec 31, 2018 | -27.74% |
| Sep 30, 2018 | -20.66% |
| Jun 30, 2018 | -17.38% |
| Mar 31, 2018 | -13.45% |
| Dec 31, 2017 | -17.77% |
| Sep 30, 2017 | -42.70% |
| Jun 30, 2017 | -59.66% |
| Mar 31, 2017 | -62.63% |
| Dec 31, 2016 | -70.14% |
| Sep 30, 2016 | -86.48% |
| Jun 30, 2016 | -167.87% |
| Mar 31, 2016 | -115.72% |
| Dec 31, 2015 | -131.87% |
| Sep 30, 2015 | -117.52% |
| Jun 30, 2015 | -91.99% |
| Mar 31, 2015 | -72.58% |
| Dec 31, 2014 | -49.52% |
| Sep 30, 2014 | -39.91% |
| Jun 30, 2014 | -40.87% |
| Mar 31, 2014 | -40.69% |
| Dec 31, 2013 | -34.45% |
| Sep 30, 2013 | -35.14% |
| Jun 30, 2013 | -51.82% |
| Mar 31, 2013 | -40.04% |
| Mar 31, 2012 | -181.06% |
| Dec 31, 2011 | -96.77% |
| Sep 30, 2011 | -69.12% |